Name | 3,3'-diindolylmethane |
---|---|
Synonyms |
HB 236
1H-Indole, 2-(1H-indol-3-ylmethyl)- 3-(1H-indol-3-ylmethyl)-1H-indole ARUNDINE di(1H-indol-3-yl)methane DI-3-INDOLYLMETHANE DIM 3-DIINDOLYL METHANE 3,3'-Diindolylmethane 1H-Indole, 3,3'-methylenebis- 2-(1H-Indol-3-ylmethyl)-1H-indole 3,3'-Methylenediindole 3,3'-Methylenebisindole;DIM DI INDOLYL METHANE di-(1H-3-indolyl)methane Indole dimer 3,3'-methylene-bis(1H-indole) 3,3-Methylenediindole Indolyl-CH2-Indolyl MFCD00195766 3,3'-Methylenebis(1H-indole) 3,3'-Diindolymetane Diindole methane |
Description | 3,3'-Diindolylmethane is a strong, pure androgen receptor (AR) antagonist. |
---|---|
Related Catalog | |
Target |
Androgen receptor[1] |
In Vitro | 3,3'-Diindolylmethane (DIM) is a strong antagonist of androgen receptor (AR) function but exhibits less than obvious structural similarity to the endogenous AR ligand, dihydrotestosterone (DHT). 3,3'-Diindolylmethane is a major digestive product of indole-3-carbinol, a potential anticancer component of cruciferous vegetables. 3,3'-Diindolylmethane exhibits potent antiproliferative and antiandrogenic properties in androgen-dependent human prostate cancer cells. 3,3'-Diindolylmethane suppresses cell proliferation of LNCaP cells and inhibits DHT stimulation of DNA synthesis. Moreover, 3,3'-Diindolylmethane inhibits endogenous PSA transcription and reduced intracellular and secreted PSA protein levels induced by DHT in LNCaP cells. Also, 3,3'-Diindolylmethane inhibits, in a concentration-dependent manner, the DHT-induced expression of a prostate-specific antigen promoter-regulated reporter gene construct in transiently transfected LNCaP cells. Co-treatment with 50 μM 3,3'-Diindolylmethane partially inhibits the translocation of AR induced by DHT treatment and showed distribution of the AR to be both cytoplasmic and nuclear. Furthermore, 3,3'-Diindolylmethane treatment prevents the formation of AR foci in the nucleus. 3,3'-Diindolylmethane alone produces a predominantly cytoplasmic distribution of fluorescence[1]. |
In Vivo | Mice are randomized into two groups and are treated daily s.c. with either vehicle or 3,3'-Diindolylmethane (10 mg/kg) for 30 days. Tumor volume and the weight of mice are recorded once every 3 days using calipers. 3,3'-Diindolylmethane (DIM) treatment resulted in a marked inhibition of SNU-484 xenograft tumor growth. Notably, the body weight of mice from both groups did not significantly differ from the vehicle control following 30 days of drug exposure, suggesting that 3,3'-Diindolylmethane has no severe toxicity to the mice. Taken together, these findings demonstrate that 3,3'-Diindolylmethane administration significantly inhibited SNU-484 xenograft growthin vivo mediated by the inactivation of YAP[2]. |
Cell Assay | The human prostate adenocarcinoma cell lines LNCaP-FGC and PC-3 are grown as adherent monolayers in 10% FBS-DMEM, supplemented with 4.0 g/L glucose and 3.7 g/L sodium bicarbonate in a humidified incubator at 37°C and 5% CO2, and passaged at ~80% confluency. Cultures used in subsequent experiments are at less than 40 passages. Cells grown in stripped conditions are in 5% DCC-FBS-DMEM base supplemented with 4 g/L glucose, 3.7 g/L sodium bicarbonate, and 0.293 g/L L-glutamine. Before the beginning of the treatments, cells are depleted of androgen for 4-7 days in medium composed of DMEM base without phenol red and with 4 g/L glucose and 3.7 g/L sodium bicarbonate. During the depletion period, medium is changed every 48 h. Treatments are administered by the addition of 1 μL of a 1,000-fold concentrated solution of 3,3'-Diindolylmethane in Me2SO/mL of medium. Once the treatment period started, medium is changed daily to counter possible loss of readily metabolized compounds[1]. |
Animal Admin | Mice[2] Four-week-old female SPF/VAF immunodeficient mice are injected subcutaneously (s.c.) into the right flank with 0.1 mL Matrigel containing 3.5×106 human gastric cancer cells (SNU-484). The mice are randomized into 2 groups 1 week after tumor implantation: i) the untreated control group (n=5, DMSO in 50 μL PBS daily) and ii) the 3,3'-Diindolylmethane-treated group (n=5, 10 mg/kg in 50 μL PBS once daily). Gastric primary tumors are excised, and the final tumor volume is measured once every 3 days using a caliper and calculated as (width)2×length/2. The experiment is terminated on day 39. Half of the tumor tissue is prepared for western blotting and the other half is snap frozen in liquid nitrogen and stored at −80°C. |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 504.8±30.0 °C at 760 mmHg |
Melting Point | 167 °C |
Molecular Formula | C17H14N2 |
Molecular Weight | 246.307 |
Flash Point | 232.5±15.8 °C |
Exact Mass | 246.115692 |
PSA | 31.58000 |
LogP | 4.05 |
Vapour Pressure | 0.0±1.2 mmHg at 25°C |
Index of Refraction | 1.765 |
Storage condition | 2-8°C |
Symbol |
GHS07 |
---|---|
Signal Word | Warning |
Hazard Statements | H315-H319-H335-H413 |
Precautionary Statements | P261-P305 + P351 + P338 |
Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
Hazard Codes | Xi |
Risk Phrases | 36/37/38 |
Safety Phrases | 22-24/25 |
RIDADR | NONH for all modes of transport |
RTECS | NM0332000 |
HS Code | 2933990090 |
Precursor 10 | |
---|---|
DownStream 3 | |
HS Code | 2933990090 |
---|---|
Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |